Cigam Lifecare Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 03-07-2024
- Paid Up Capital ₹ 0.10 M
as on 03-07-2024
- Company Age 13 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue 86.79%
(FY 2021)
- Profit 37.55%
(FY 2021)
- Ebitda 34.95%
(FY 2021)
- Net Worth -49.12%
(FY 2021)
- Total Assets -5.60%
(FY 2021)
About Cigam Lifecare
The Corporate was formerly known as Caddiline Exports Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Nishant Makhe and Sujit Gulalkari serve as directors at the Company.
- CIN/LLPIN
U24233MH2011PTC223865
- Company No.
223865
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Nov 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Nagpur, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Cigam Lifecare Private Limited offer?
Cigam Lifecare Private Limited offers a wide range of products and services, including TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Anti Infective Drugs & Medicines, Anti Allergic Drug, Cardiovascular Drugs & Medication, Cardiac Drugs, Common Disease Medicines, Pharmaceutical Tablets, Pain Relief Drugs & Pharmaceuticals, Osteoporosis Medications.
Who are the key members and board of directors at Cigam Lifecare?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sujit Gulalkari  | Director | 12-Nov-2011 | Current |
| Nishant Makhe | Director | 02-Jan-2015 | Current |
Financial Performance of Cigam Lifecare.
Cigam Lifecare Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 86.79% increase. The company also saw a substantial improvement in profitability, with a 37.55% increase in profit. The company's net worth observed a substantial decline by a decrease of 49.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cigam Lifecare?
In 2021, Cigam Lifecare had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Cigam Lifecare?
Unlock and access historical data on people associated with Cigam Lifecare, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cigam Lifecare, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cigam Lifecare's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
